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INTRODUCTION 
This thesis presents experiments designed to further 
our understanding of the immunological mechanism of action 
of GRl 784, a novel synthetic nucleoside drug. Previous 
observations have indicated that GR1784 may have potential 
pharmaceutical applications in a number of immunological 
conditions, in particular the recovery from 
immunosuppression induced by exposure to X-irradiation or 
administration of cytotoxic drugs. 
The important questions answered in this thesis are : 
1) Can GR1784 exert immunomodulation upon a normal, 
healthy immune system or only upon a damaged immune system 
(as previously observed)? 2) What are the effects of 
GRl 784, if any, upon certain hematopoietic and cellular 
immune parameters subsequent to immunosuppression? 
In order to address these questions, the drug was 
administered to groups of normal and immunosuppressed mice 
in vivo, while temporally assessing its hematological and 
immunological effects upon a number of cell populations in 
vitro. 
The agent chosen to induce immunosuppression in these 
studies was cyclophosphamide (Cy). The previously observed 
immunopotentiating effects of GR1784 were made in animal 
1 
2 
models of immunosuppression induced by exposure to x-
irradiation or administration of Cy. The parameters 
assessed in these studies have been shown to be affected in 
very similar ways by either of these two hematological 
insults. Cy was preferred because of its ease of 
administration and more reproducible immunosuppression. 
The hematological parameters followed were 1) 
Peripheral blood leukocyte count (PBLC), 2) spleen weight 
and spleen weight index ( s. W. I. ) , 3) bone marrow and 
spleen cellularity and 4) bone marrow and spleen colony 
forming units (CFU's). The cellular immune parameters 
followed were 1) Splenic T lymphocyte mitogenesis, as 
assessed by response to Concanavalin A (Con A) and 2) 
splenic B lymphocyte mitogenesis, as assessed by response 
to Lipopolysaccharide (LPS). 
These parameters provided an indication of both the 
quantity and functional responsiveness of cell populations 
at various stages of differentiation, ranging from 
pluripotent progenitor stem cells of the bone marrow to 
fully differentiated and mitogen responsive lymphocytes of 
the spleen. In addition, these parameters have all been 
shown to be affected by the administration of Cy at the 
doses employed in these studies. 
LITERATURE REVIEW 
GR1784 is a Xanthosine analog that belongs to a 
family of nucleoside drugs, one of which, Isoprinosine, is 
in clinical use throughout much of the world as an 
antiviral agent (for review see 1). GR1784 is the ion pair 
formed between the Choline cation and the Xanthosinate 
anion. It is the product of a neutralization reaction that 
occurs in aqueous solution by the mixing of equimolar (0.4 
M) quantities of Choline Hydroxide (in Methanol) and 
Xanthosine.2H2o. The white Choline Xanthosinate 
precipitate is formed at a temperature of 80 • c and is 
lyophilised to dryness. 
This unusual ion pair association was strongly 
suggested by Infra Red (I.R.) spectroscopy (Gordon, P. and 
Ferraro, J., 1985, unpublished data), pH and conductivity 
data (Gordon, P., 1984, unpublished data). I .R. 
spectroscopy on solid Choline Xanthosinate in KBr showed no 
spectral peak shifts compatible with the formation of new 
covalent bonds. Furthermore, the pH in 0.1 M solution of 
this salt of a strong base and weak acid was 7.10. This 
contrasted sharply with the pH of a salt formed between the 
Sodium cation and Xanthosinate anion, which was 10. 48 in 
0.1 M solution. In the absence of any covalent 
interaction, this argues strongly for the formation of an 
3 
4 
ion pair between the Choline cation and Xanthosinate anion. 
Lastly, the conductivity of Choline Xanthosinate was also 
anomalous : Whereas the equivalent conductivity of Sodium 
xanthosinate paralleled that of an ionic salt (NaCl), that 
of choline Xanthosinate was dramatically reduced over the 
same range of concentrations. 
formation of an ion pair. 
This again argues for the 
Its neutral pH, together with its good solubility in 
aqueous solvents, make GR1784 ideal for safe pharmaceutical 
application. A caveat to its administration in liquid 
form, is that it is unstable in aqueous solution. It has 
been shown to be 67 % hydrolyzed into one of its 
constituents, Xanthine, after 7 days in distilled water 
(Landis, R.C., 1984, unpublished data). 
While no pharmacologic properties have been 
previously reported for Xanthosine or its analogs, 
unpublished data from this laboratory, employing both 
animal models and in vitro culture systems, suggest that 
GR1784 may possess immunoregulatory properties. For 
example, GR1784 has been shown to provide significant 
protection towards lethal and sublethal X-irradiation in 
Fisher F344 rats (Gordon, P. and Wepsic, T •' 1985, 
unpublished data). In a rat model of chronic Cy induced 
immunosuppression, GR1784 was shown to exhibit 
immunorestorative properties similar to those previously 
reported for Isoprinosine (2). Using Isoprinosine as an 
5 
internal control, a significant reversal of Cy 
cytotoxicity, with respect to body weight and spleen 
weight, was demonstrated. In addition, a partial (not 
significant) restoration of depressed Con A mitogenesis was 
observed, which was at least as effective as that achieved 
by Isoprinosine (Gordon, P., 1985, unpublished data). In 
contrast to these immunopotentiating properties, GR1784 was 
also shown to significantly enhance the formation of 
suppressor cells (Gordon, P., 1985, unpublished data), in 
an in vitro model of Con A induced suppressor cell 
generation (3). 
These findings suggest that GR1784 may possess 
immunomodulating properties very similar to those ascribed 
to Isoprinosine (4, 5, 6). 
The C57Bl/6 mouse model was used because it has been 
widely employed as a standard model in which to perform X-
irradiation and Cy cytotoxici ty studies ( 9, 10, 11, 12, 
13) . 
Cy was chosen as the agent with which to induce 
hematosuppression in an attempt to combine the previously 
observed radiation protection and Cy cytotoxicity reversal 
data of GR1784 into a unified mechanism of action. 
The four hematopoietic parameters assessed (see 
Introduction) have all been shown to be affected in 
basically similar ways by both X-irradiation and Cy 
administration in both rats and mice (13, 14, 15, 16). The 
6 
chronological order of events following recovery from 
either of these two hematological insults has been shown to 
be the same : survival and recovery of the pluripotent 
hematopoietic stem cells in the bone marrow and subsequent 
repopulation of depleted mature cell compartments in the 
peripheral blood, spleen and bone marrow (17, 18, 19, 20). 
The CFU parameter is a measure of the colony forming 
capacity of an early stem cell population that represents 
the first link in the chain of events leading to recovery 
following hematological insult. The possibility that 
GR1784 could be acting as a radioprotector (Gordon, P. and 
Wepsic, T., 1985, unpublished data) by stimulating 
hematopoiesis is therefore also investigated. This 
possibility is also consistent with its significant 
restoration of the spleen weight index during Cy 
immunosuppression in rats (Gordon, P., 1985, unpublished 
data). 
The parameters that measure differentiated cell 
numbers are important not only because they ref le ct the 
recovery of pluripotent stem cells but also because they 
can provide information on any potential direct protection 
of mature cells by GR1784. 
Another means by which GR1784 might be exerting its 
radioprotective effects is by increasing the immunological 
responsiveness of the surviving lymphocyte compartment 
following X-irradiation. Such a mechanism of action was 
7 
examined by assessing the responsiveness of splenic 
lymphocytes to both T & B cell mi togens at several time 
points following Cy administration. 
The various hematopoietic and mi togenic parameters 
outlined above were assessed on days 2, 5, 9 & 16 following 
Cy administration on day o. This was necessary due to the 
dynamic nature of both the circulating lymphocyte (13, 21, 
23) and hematopoietic stem cell compartments (8, 12, 15, 
16, 17, 18, 19, 20, 21 and for review 22) following Cy 
treatment. The assay days were chosen to reflect the three 
phases of; depression, rebound, and normalisation, 
characteristic of Cy immunosuppression. In normal mice 
these time points represented days following the beginning 
of the GRl 784 treatment regimen. This selection of time 
points therefore permitted the detection of both early and 
late potential drug effects of GR1784 in normal mice. 
MATERIALS AND METHODS 
Materials Concanavalin A (Con A) and Pokeweed Mitogen 
(PWM) were purchased from Sigma Chemical Corporation (St. 
Louis, MO). Hanks balanced salts solution (HBSS), fetal 
calf serum (FCS), Eagles MEM essential amino acids, Eagles 
MEM non-essential amino acids and sodium pyruvate were 
purchased from Grand Island Biological Company (Grand 
Island, NY) . RPMI 1640, L-glutamine, Penicillin/ 
Streptomycin (10000 U/ml & 10000 J-A9'/ml) and HEPES buffer 
were purchased from Irvine Scientific (Santa Ana, CA). ~ 
coli 0127: BS LPS and bacto DIFCO agar was purchased from 
DIFCO Laboratories (Detroit, MI). Flat bottomed 96 well 
microtiter plates and 35 mm2 plastic petri dishes were 
purchased from Falcon laboratories (Oxnard, CA). 3H-
Thymidine (6.7 mCi/mol) was purchased from ICN Chemicals & 
Radioisotope Division (Irvine, CA). Pseudocumene 
scintillation liquid was purchased from Beckman instruments 
Inc. (Fullerton, CA). 
Mice Male C57Bl/6NCR mice, 22 weeks old, were purchased 
from Charles River Laboratories (Wilmington, MA) and were .. 
used in the Cy dose titration and colony stimulating factor 
{CSF) titration experiments. The age of these mice, well 
8 
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past the optimum for mitogenic studies, was deemed 
acceptable for the purposes of titration of a CSF source. 
Unknown CSF activity was determined by comparison with a 
known CSF standard. Female C57Bl/6 mice, 8-10 weeks old, 
were purchased from Cumberland View Farms (Clinton, TN} and 
were used in the experiments examining the immunomodulating 
effects of GR1784. Male CBA/2J mice, 22 weeks old, were 
purchased from Jackson Laboratories (Bar Harbour, Maine) 
and were used to prepare spleen conditioned growth medium 
for the CFU experiments. 
Drugs Cyclophosphamide [Neosar) was purchased from Adria 
Laboratories (Columbus, Ohio) and was injected intra 
peritoneally (i.p.) at either 150 or 200 mg/kg body weight 
on day o. GR1784 (Dr. P. Gordon, Loyola University of 
Chicago, Maywood, IL) was prepared in physiological saline 
and was injected sub cutaneously (s.q.) at 0.1 mg/kg/day, 
the dose shown to most effective in previous 
radioprotection studies (Gordon, P. and Wepsic, T., 1985, 
unpublished data). It was prepared freshly each day 
immediately prior to use, because of its labile nature in 
aqueous solution (see Literature Review). 
Peripheral blood leukocyte count CPBLCl Peripheral blood 
was obtained by retroorbital puncture, diluted in 
physiological saline to 1 % and counted, after erythrocyte 
10 
lysis, with a Hycel automated cell counter (Hycel Co. , 
Houston, TX) . 
Spleen weight and spleen weight index cs. W. I. ) Spleens 
were removed aseptically, all excess fat trimmed away and 
each weighed individually on sterile gauze pads. The 
spleen weight index is the spleen weight as a percent of 
body weight and is defined by the equation (spleen 
weight/body weight) x 100. 
Bone marrow and spleen cell preparations Spleens and hind 
leg femurs were removed observing sterile technique and 
single cell suspensions made by homogenising individual 
spleens with ground glass homogenisers and washing out 
femurs with HBSS using a 22 gauge syringe. Nucleated cells 
from individual animals were counted in Turk's stain. Cell 
viabilities were also determined by Trypan Blue dye 
exclusion of pooled cell populations. Cell counts 
represent the average ± S.E. of total spleen and total bone 
marrow/femur cell numbers for each treatment group. 
Splenic lymphocyte mitogenesis The mice used in the Cy 
titration experiment were male C57Bl/6NCR (Charles River 
Laboratories, Wilmington, MA) and in the GR1784 
immunomodulatlon experiment female C57Bl/6 (CUmberland 
View Animal Farms, Clinton, TN). Individual spleen cell 
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suspensions were pooled for each treatment group and washed 
3 x with HBSS. The final resuspension was in culture 
medium {RPMI 1640 supplemented with 10 % FCS, 100 U/ml 
Penicillin, lOOJ..Lg/ml Streptomycin, 2 mM L-glutamine, 20 mM 
HEPES buffer and 50 _r.M 2-Mercaptoethanol). Nucleated 
spleen cells were counted in Turk's stain and viability 
determined in 0.04 % Trypan Blue. Cells were placed at 2 x 
105 cells/well in flat bottomed 96 well microtiter plates 
and incubated in the presence of mitogen for 72 h at 37•C 
Con A was included at 0.5, 1.0, 3.0 & 5.0 
.,Mg/ml and LPS at o. 5, 1. O & 2. o .rg/ml. Cells were pulsed 
with 3H-Thymidine over the last 18 h of incubation. They 
were harvested and then counted for radioactive decay in 
the 3a channel using a Beckman LS 5801 scintillation 
counter. counts represent average ± S.E. DPM's of 
triplicate wells. 
Generation of colony stimulating factor CCSF-C.L.) Pooled 
spleens from two male CBA/2J mice were homogenised and 
washed 3 x with HBSS. The final resuspension was in 
culture medium {RPMI 1640 supplemented with 10 % FCS, 100 
U/ml Penicillin, 100.f"9'/ml Streptomycin, 2 mM L-glutamine, 
20 mM HEPES buffer and 50J4M 2-Mercaptoethanol). Nucleated 
cells were counted in Turk's stain. CSF was generated by 
incubating 50 ml spleen cells, at 2x 106 cells/ml, with 0.2 
ml 1 % PWM for 7 days at 37•C and 5 % co2 • The supernate 
12 
was removed, vacuum filtered (pore size 45~m) and stored 
at -2o·c until required. 
colony forming unit C CFU) assay Bone marrow and spleen 
CFU' s were measured by employing a soft agar assay ( 12) . 
specifically, spleen and bone marrow cell suspensions from 
individual animals were pooled for each treatment group and 
were washed 3 x with HBSS. The final resuspension was in 
RPMI 1640 (supplemented with 15 % FCS, 0.045 % sodium 
bicarbonate, 1 mM sodium pyruvate, 0.8 % Eagles MEM 
essential amino acids (lOOX), 0.4 % Eagles MEM non-
essential amino acids (lOOX), 0.4 % Eagles MEM vitamins 
(lOOX), 0.8 mM L-glutamine, 50 U/ml Penicillin and 50J>9/ml 
Streptomycin). Nucleated spleen and bone marrow cells were 
counted in Turk's stain and viability determined in 0.04 % 
Trypan Blue. O. 7 ml bone marrow or spleen cell 
suspensions, at a final concentration of 7. 5 x 104 bone 
marrow and 7. 5 x 105 spleen cells/ml, were mixed at 37 • c 
with 0.1 ml 3 % molten bacto DIFCO agar and plated in 35 
mm2 petri dishes containing 0.2 ml of the CSF source. PWM 
spleen conditioned CSF source was included at O & 25 .r-1 
volumes for each treatment group. CSF-C.L. was prepared as 
described above and CSF-R. Y. was the gift of Rita Young 
(Department of Pathology, Loyola University, Maywood IL). 
The number of colonies ( > 50 cells) per 35 mm2 petri dish 
was determined microscopically at 40 x magnification after 
13 
5 days incubation at 37•C and 5 % co2 • CFU counts 
represent the average ± S.E. number of colonies/petri dish. 
Background colony counts, occurring in the absence of an 
exogenously added CSF source, were subtracted for each 
determination. 
statistics The students t test was used to evaluate 
differences between treatment groups, significance being 
attributed at P values < o.os. 
RATIONALE 
The experiments presented in this thesis are 
concerned with studying the effects of GR1784 upon a number 
of immunological parameters in normal and Cy 
immunosuppressed mice. Two important steps that had to be 
taken before this study could be initiated, however, were a 
determination of the Cy dose used to induce 
immunosuppression and a standardisation of the two in vitro 
culture assays employed, the mitogenesis and CFU assays. 
The remainder of the parameters pertained to determination 
of spleen weight and quantitation of several hematological 
cell populations. These did not require standardisation 
before evaluation of their response to GR1784 treatment. 
A Cy dose titration was therefore first performed, 
following the suppression of lymphocyte mi togenesis as a 
measure of immunosuppression. A dose of Cy was selected 
that resulted in a significant suppression of mitogenesis 
but not so large as to overshadow any potential 
immunorestorative effects of GR1784. This experiment also 
served the dual purpose of standardising the B and T 
lymphocyte mitogenesis assays for subsequent use. 
The other in vitro assay that required 
standardisation was the soft agar CFU assay of bone marrow 
14 
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and spleen. This measures the colony forming response of 
progenitor cells to an exogenously added colony stimulating 
factor (CSF) source. Such a CSF source was obtained from 
Pokeweed mitogen (PWM) conditioned spleen cells, as 
described in Materials and Methods, and was assayed for 
colony stimulating activity against a positive control in a 
standard soft agar CFU assay. The dose of CSF source used 
in subsequent assays was therefore established at the same 
time as standardising the CFU assay. 
With these preliminary experiments completed, the 
main study assessing the potential immunomodulating effects 
of GR1784 in C57Bl/6 mice, was undertaken. 
RESULTS 
Cy d.ose titration Suppression of splenic lymphocyte 
mitogenesis 
Cy was observed to exert a dose dependent suppression 
of both B and T lymphocyte mitogenesis with respect to 
untreated control animals (Fig 1.). This suppression 
became more pronounced with time, reaching maximum levels 
on the last assay point, 9 days following Cy treatment. 
The suppression of B lymphocyte mitogenesis, as assessed by 
response to LPS, was more profound than the suppression of 
T lymphocyte mitogenesis, as assessed by response to con A. 
suppression of T lymphocyte mitogenesis by 150 mg/kg 
and 200 mg/kg Cy varied from 13 % (N.S.) and 16 % (P < .02) 
respectively on day 3, to 40 % and 70 % (P < .001 in each 
case) respectively on day 9. In comparison, B lymphocyte 
mi togenesis was already significantly suppressed by both 
doses on day 3 (P < • 001 in each case) • Suppression 
increased steadily with time and reached 79 % and 92 % for 
the 150 mg/kg and 200 mg/kg doses respectively on day 9. 
The Cy dose of 150 mg/kg was chosen to induce 
immunosuppression in subsequent studies investigating the 
potential immunomodulating effects of GR1784. 
16 
17 
Figure 1 Cy dose titration: Suppression of splenic B & 
T cell mitogenesis. Male C57Bl/6NCR mice (n=5) were 
injected i.p. on day o with either saline or Cy at 150 
mg/kg (open symbols) or 200 mg/kg (closed symbols). 
Spleens were removed on days 3 , 6 & 9, homogenised and 
seeded into 96 well microtiter plates at a concentration 
of 2 x 105 cells/well. Cells were incubated for 72 h at 
37•C and 5 % co2 with either media alone, Con A at 3 
-J-<J/ml (triangles) or LPS at 1 .,ug/ml (squares). 3H-
Thymidine uptake over the last 18 h of incubation was 
assessed by liquid scintillation spectroscopy. Counts 
represent the average ± S.E. DPM's of triplicate wells, 
expressed as a % of untreated controls. 
2 
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Cy dose titration 
-----· 
3 4 5 6 7 
Days post cyclophosphamlde 
8 9 10 
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CSF TITRATION 
# of Colonies/Culture 
A) B) 
jA-1 CSF CSF source Bone Marrow Spleen 
0 1 ± 0.6 0 
25 C.L. 188 ± 18.6 21.0 ± 2.0 
25 R.Y. 142 ± 3.2 15.0 ± 1.5 
50 C.L. 250 ± 8.5 25.3 ± 2.9 
50 R.Y. 170 ± 10.5 18.3 ± 1.8 
Table 1 Titration of the CSF preparation for activity in a 
CFU assay The PWM induced CSF preparation, CSF C.L. (see 
Materials and Methods) was compared for colony stimulating 
activity with a positive control, CSF R.Y., in a soft agar 
Colony Forming assay. Final 1 ml reaction mixtures 
contained A) 7.5 x 104 Bone Marrow cells or B) 7.5 x 105 
spleen cells, 0.3 % bacto DIFCO agar and CSF at the volumes 
indicated. Colonies ( > 50 cells) were counted 
microscopically at 40 X magnification after 5 days 
incubation at 3 7 • c and 5 % co2 • Numbers represent the 
average colonies ± s.E. per 35 mm2 petri dish of triplicate 
reaction mixtures. 
20 
CSF production and dose titration 
The CSF source to be used in subsequent CFU assays, 
CSF C.L., was prepared from PWM conditioned CBA/2J 
splenocytes as described in Materials and Methods. 
then titrated for colony stimulating activity 
It was 
with a 
positive control, CSF R.Y., in a standard soft agar colony 
forming assay (Table l). 
Both CSF sources were shown to possess significant 
colony stimulating activity, when included in reaction 
mixtures at volumes of 25 ~l and 50 .J"-1• The colony 
stimulating activity of CSF C.L. was greater than that of 
the positive control, CSF R.Y. In fact, CSF C.L. possessed 
a colony stimulating activity at 25.,ul approximately equal 
to that of CSF R.Y. at double that volume. 
Effect of GRl 784 upon hematopoietic parameters in normal 
and Cy immunosuppressed mice 
l) Peripheral Blood Le.ukocyte Count CPBLC) 
In normal mice, GR1784 was observed to cause a 
significant depression of PBLC's on days 2 (P < .05) and 9 
(P < .02), but not on days 5 and 16 (Fig. 2.). A steady 
increase in the PBLC level was also observed in the·, 
untreated control group as the study progressed, indicating 
a certain amount of variability in the assay. 
The administration of 150 mg/kg Cy caused a 
significant depression (P < .001) of PBLC's to 30 % of 
21 
Fig 2 Effect of GRl 784 upon PBLC' s in normal and Cy 
immunosuppressed mice\ Female C57Bl/6 mice were 
injected i.p. on day O with either saline (circles) or 
150 mg/kg CY (triangles). Open symbols represent control 
groups and closed symbols GR1784 treated groups (O.l 
mg/kg/day, s.q.). Blood was obtained on days 2, 5, 9 & 
16 by retroorbital puncture, diluted in physiological 
saline to 1 % and counted, after erythrocyte lysis, on a 
Hycel automated cell counter. Points represent the 
average ± S.E. PBLC's from 5 animals. 
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untreated control levels. While a gradual return to normal 
was observed on days 9 and 16, PBLC levels still remained 
significantly depressed on these days (P < .002 and P < .01 
respectively). GR1784 had no significant effect upon 
PBLC's in Cy immunosuppressed mice. 
2) Spleen weight and s.w.I. 
Both spleen weight and S.W.I. expressed very clearly 
the three phases characteristic of CY cytotoxicity 
Significant spleen weight depression on days 2 and 5 (P < 
.001), significant rebound and splenomegaly on day 9 (P < 
.001) and complete normalisation by day 16 (Fig. 3a. & b.). 
There was clearly no GRl 784 treatment effect upon 
either of these parameters in either normal or Cy 
immunosuppressed mice. 
3) Spleen and bone marrow cellularity 
The response of spleen cellulari ty was observed to 
follow that of spleen weight very closely (Fig. 4a.), 
exhibiting the three phases of Cy cytotoxici ty described 
above. There was no GRl 784 treatment effect upon spleen 
cellularity in either normal or Cy immunosuppressed. 
Bone marrow cellularity was significantly depressed 
by Cy on day 2 (P < .001), levels returning to normal by 
days 9 and 16 (Fig. 4b.). No rebound phase similar to that 
described for spleen cellularity was observed. No GR1784 
24 
Fig. 3 a. & b. Effect of GR1784 upon spleen weight and 
S.W.I. in normal and Cy imrnunosuppressed mice. Female 
C57Bl/6 mice were injected i.p. on day o with either 
saline (circles) or 150 mg/kg CY (triangles). Open 
symbols represent control groups and closed symbols 
GR1784 treated groups (O.l mg/kg/day, s.q.). Spleens 
were removed and weighed on days 2, s, 9 & 16. Spleen 
Weight Index is defined by the equation : (spleen 
weight/body weight)xlOO. Points represent A) the average 
spleen weight ± S.E. (in mg) or B) the average s.w.I. ± 
S.E. of 5 animals. 
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Fig. 4a. & b. Effect of GR1784 upon bone marrow & spleen 
cellularity in normal and Cy immunosuppressed mice. 
Female C57Bl/6 mice were injected i.p. on day o with 
either saline (circles) or 150 mg/kg CY (triangles). 
Open symbols represent control groups and closed symbols 
GR1784 treated groups (O.l mg/kg/day, s.q.). Spleens and 
hind leg femurs were removed on days 2, 5, 9 & 16. A) 
Spleens were homogenised using a ground glass homogeniser 
and B) femurs were flushed using a 22 gauge needle. 
Nucleated cells were counted in Turk's stain. Points 
represent the average ± s. E. nucleated cells/spleen or 
hind leg femur of 5 animals. 
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related drug effects were observed on this parameter in 
either normal or Cy immunosuppressed mice. 
4) Spleen and bone marrow CFU's 
Bone marrow CFU's were rapidly elevated by Cy on day 
2 to 350 % of untreated control levels. They passed 
through normal levels on day 5 and rebounded to 15 % of 
untreated control levels on day 9 (Fig. 5a.). There was no 
GR1784 treatment effect in either normal or 
immunosuppressed mice. 
Spleen CFU's were unchanged by Cy on day 2 but became 
dramatically elevated on days 5 and 9 to 800 % and 1700 % 
of untreated control levels respectively (Fig. 5b.). 
GR1784 exerted no effect upon this parameter in 
immunosuppressed mice. In normal mice, however, it 
significantly depressed spleen CFU's to 40 % and 37 % of 
untreated control levels on days 5 and 9 respectively (P < 
.01 in each case), but not on day 2. 
Effect of GR1784 upon T & B cell mitogenesis in normal and 
immunosuppressed mice 
In confirmation of the results observed in the Cy 
dose titration experiment (Fig. 1), the suppressive effect 
of 150 mg/kg Cy was more profound on B lymphocyte 
mitogenesis than T lymphocyte mitogenesis (Fig. 6a. & b.). 
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Fig. Sa. & b. Effect of GRl 784 upon bone marrow and 
spleen CFU's in normal and Cy immunosuppressed mice. 
Female C57Bl/6 mice were injected i.p. on day o with 
either saline (circles) or 150 mg/kg CY (triangles) . 
Open symbols represent control groups and closed symbols 
GR1784 treated groups (O.l mg/kg/day, s.q.). Single cell 
suspensions were obtained (see Materials and Methods) on 
days 2, 5 & 9 and tested for A) bone marrow and B) spleen 
colony forming capacity in a standard soft agar colony 
·forming assay. Final 1 ml reaction mixtures contained 
7.5 x 104 bone marrow cells, 7.5 x 105 spleen cells, 0.3 
% bacto DIFCO agar and 25J'"'l CSF. Colonies were counted 
microscopically at 40 X magnification after 5 days 
incubation at 37 • c and 5 % co2 . Points represent the 
average ± S.E. CFU's of 5 animals, expressed as a % of 
untreated controls. 
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Fig. 6 a. & b. Effect of GR1784 upon T and B lymphocyte 
mi togenesis in normal and Cy immunosuppressed mice. 
Female C57Bl/6 mice were injected i.p. on day o with 
either saline (circles) or 150 mg/kg CY (triangles). 
Open symbols represent control groups and closed symbols 
GR1784 treated groups (O.l mg/kg/day, s.q.). Spleens 
were removed on days 2, 9 & 16, homogenised and seeded 
into flat bottomed 96 well microtiter plates at a 
concentration of 2 x 105 cells/well. Cells were 
incubated for 72 h at 37·c and 5 % co2 with media alone 
or in the presence of A) LPS at lj4-9/ml or B) Con A at 3 
JoUJ/ml 3H-Thymidine uptake over the last 18 h of 
incubation was assessed by liquid scintillation 
spectroscopy. Points represent the average ± S.E. DPM's 
of triplicate wells, expressed as a % of untreated 
controls. 
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B lymphocyte mitogenesis, as assessed by response to LPS, 
became significantly suppressed through days 2 to 9 (P < 
.001 in each case), to 10 % of untreated control values. T 
lymphocyte mitogenesis, as assessed by response to Con A, 
became significantly suppressed through these study days to 
25 % of untreated control values (P < .001 in each case). 
However, at the additional 16 day time point, neither T nor 
B lymphocyte mitogenesis were still significantly 
depressed. 
There was no significant GR1784 treatment effect upon 
B cell mi togenesis in either normal or immunosuppressed 
mice. There was, however, a significant decrease in T cell 
mitogenesis on day 9 (P < .05), but not on days 2 and 16, 
in normal mice. There was also a significant elevation in 
T cell mi~ogenesis on day 2 (P < .02), but not on days 9 
and 16, in immunosuppressed mice. The elevation in T cell 
mi togenic responsiveness in immunosuppressed mice was of 
particular interest, since it might provide a partial 
explanation, at least, for the radioprotective properties 
of GR1784. 
DISCUSSION 
The experiments described in this thesis were 
designed to answer two basic questions : l) Could GR1784 
act as a pure immunostimulant in the context of an 
undamaged immune system? 2) could previously observed 
immunorestorative properties of GR1784 be explained by an 
increase in hematopoiesis or an enhancement of lymphocyte 
function following hematological insult? 
With respect to the first question, PBLC's were 
significantly depressed on days 2 and 9 but were unchanged 
on days 5 and 16 (Fig. 2). However, standard error bars 
were relatively large and the untreated control values 
could not be reproduced over all study days. Taking these 
factors and the lack of any effect in immunosuppressed mice 
into consideration, it was concluded that GRl 784 had no 
reproducible effect on PBLC in normal mice. 
A significant depression of spleen CFU' s was also 
observed on days 5 and 9, although not on day 2 (Fig. Sb). 
It must be noted, however, that untreated control levels of 
colony counts could not be repeated from one assay day to 
the next (varying as much as by a factor of 5) and were·. 
therefore normalised with respect to each other by 
expressing them as 100 % untreated control counts for that 
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day. Spleen colony counts on days 5 and 9 were unusually 
low, being < 10 colonies/petri dish. A high degree of 
error could therefore be expected by comparing treatment 
groups with untreated controls on those days. Assuming, 
for the sake of discussion, that these values do represent 
a true indication of the effect of GR1784 upon spleen CFU's 
in normal mice, then such an observation could be explained 
by an advanced maturation state of the colony forming cells 
(CFC's) that are measured by the CFU assay and their 
subsequent transport into the peripheral blood stream. 
such an event would also predict elevated PBLC levels on 
these assay days. PBLC levels, however, remained unchanged 
or were even slightly ''depressed on these days (Fig. 2), as 
already discussed above. It was therefore concluded that 
GR1784 treatment had no consistent effect upon spleen CFU's 
in normal mice. 
None of the other parameters showed any reproducible 
GRl 7 8 4 treatment effects in normal mice. It is therefore 
concluded that GRl 784 exhibits no direct immunoregulatory 
properties in normal mice consistent with its previously 
observed immunopotentiating effects in immunosuppressed 
animals. 
With respect to the second question, the parameters 
chosen for study could be broken down into two broad 
categories Those pertaining to early stem cell 
populations and those pertaining to relatively mature cell 
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populations. The parameters that measured early stem cell 
populations were bone marrow CFU' s and bone marrow 
cellularity. The spleen is a visceral hematopoietic organ 
that has been shown to be particularly erythropoietic and 
granulopoietic following hematological insult (29, 30). 
The spleen CFU and cellularity parameters therefore 
referred to a committed granulocyte cell population that 
was at an intermediary stage of differentiation. The PBLC 
parameter and the splenic lymphocyte mitogenesis response 
referred to mature cell populations. The mitogenic 
parameter, however, is an indicator of mature lymphocyte 
function and will be ~~iscussed later, separately from the 
other hematopoietic pa~ameters. 
One possible mechanism of immunorestoration by GR1784 
following X-irradiation or CY administration is a direct 
sparing effect upon mature cell populations. The 
parameters pertaining to such cell populations are PBLC, 
spleen weight, spleen cellularity and spleen CFU's. 
Cy induced a pronounced depression of PBLC levels on 
days 2 and 5 that gradually disappeared through days 9 and 
16 (Fig. 2). This leukopenia was in good agreement with 
the results of others which showed PBLC's in C57Bl/6 mice 
to be depressed to 27 - 33 % of control levels by 200 mg/kg 
Cy on days 1 to 5, with a gradual return to normal being 
observed by day 20 (21). GR1784 treatment had no effect on 
the rate of PBLC recovery following Cy administration. 
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Analysis of spleen weight and S. W. I. revealed the 
three phases of depression, rebound and normalisation that 
are characteristic of Cy cytotoxicity (Fig. 3a & 3b). 
These results were in good agreement with previous 
observations in C57Bl/6 mice treated with 200 mg/kg Cy, 
which demonstrated spleen weight depression on days l to 5, 
splenomegaly on day 9 and a return to normal on day 17 (12, 
28). GR1784 treatment had no effect on the recovery of 
either of these parameters following Cy administration. 
Spleen cellularity was shown to closely mirror spleen 
weight following Cy treatment (Fig. 4a.). The spleen has 
been shown to function primarily as an erythropoietic and 
granulopoietic organ following hamatosuppression (29, 30). 
Therefore, the rebound phase represented an increase in the 
number of immature neutrophils that subsequently went on to 
repopulate the peripheral blood leukocyte pool. These 
findings were consistent with other reports which utilised 
both C57Bl/6 and BDF1 mice and a Cy dose of 200 mg/kg (21, 
31). 
The enormous elevation of spleen CFU levels observed 
in Fig. Sb following Cy administration was in excellent 
agreement with previous reports, in which 200 mg/kg Cy 
caused elevations in splenic CFU's of 1200 % and 2400 % on 
days 7 and 9 respectively (12, 21). In corroboration of 
the findings with spleen weight and spleen cellularity, 
GR1784 treatment had no effect upon spleen CFU's following 
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Cy administration. 
Another possible mechanism of hematorestoration is an 
increased level of hematopoiesis in the bone marrow. The 
two parameters relevant to hematopoiesis are bone marrow 
cellularity and bone marrow CFU's. 
In accordance with previous findings (12, 21, 31), 
bone marrow cellularity did not rebound in a similar manner 
to spleen cellularity following Cy administration, but 
rather returned to normal more gradually beginning at day 5 
(Fig. 4b.). Hematopoietic recovery from the cytotoxic 
effects of Cy has been shown to be initiated in the bone 
marrow by pluripotent stem cells (19, 21, 31). These are 
less sensitive to Cy than the rapidly cycling colony 
forming cells (CFC's) and respond to the cytotoxic effects 
of Cy administration by rapidly repopulating the depleted 
CFC pool. As these pluripotent stem cells differentiate 
and expand they are transported out of the bone marrow to 
peripheral hematopoietic organs, such as the spleen, where 
they undergo clonal expansion in response to their new 
microenvironment (31). The rebound phase characteristi-
cally observed in the spleen cell compartment following Cy 
administration was therefore not observed in the bone 
marrow compartment, due to the continual export of this 
differentiating cell population. Again, there was no 
GR1784 treatment effect in Cy immunosuppressed mice. 
The CFU parameter provides a measure of the number of 
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CFC's in the bone marrow (11, 31). This is a stem cell 
population of the macrophage-granulocyte lineage that has 
been shown to behave in a similar manner to another stem 
cell population, commonly referred to as endogenous colony 
forming units (e-CFU's). Recovery following X-irradiation 
and Cy administration has been correlated closely to the 
number of surviving e-CFU's in the bone marrow (32, 33, 
34). Survival of these stem cells ensures their subsequent 
differentiation into mature functional elements of the 
reticuloendothelial system, where they help cope with the 
surgence of endogenous pathogens that secondarily cause 
death 10 to 20 days following Cy treatment or X-irradiation 
( 3S) . 
The early destruction of bone marrow CFC' s reported 
previously ( 10, 12, 21) was not observed in this study, 
most likely because the Cy insensitive pluripotent stem 
cells had already repopulated the bone marrow CFC 
population by the time of the first assay point on day 2 
(Fig. Sa.). In keeping with previous findings (10, 22), 
the elevated bone marrow CFU levels on day 2 returned back 
to normal by day s, concomitant with the transport of CFC's 
out of the bone marrow to secondary hematopoietic organs. , 
No significant elevation of bone marrow CFU' s consistent 
with a hypothesis of hematorestoration via increased 
hematopoiesis was observed in immunosuppressed mice treated 
with GR1784 (Fig. Sa). These results were consistent with 
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a similar lack of treatment effect observed for bone marrow 
cellularity (Fig. 4b). 
Most radiation protectants are only effective when 
administered 1 day prior to irradiation (7, 34, 36, 37, 
38). This has been correlated with the time required to 
stimulate the differentiation of progenitor cells into a 
less radiation sensitive intermediate (40). GR1784, 
however, has been shown to exert radioprotective properties 
with treatment beginning 1 day post irradiation (Gordon, P. 
and Wepsic, T., 1985, unpublished data). A potential 
mechanism of action is therefore more likely to be an 
increased functional responsiveness of surviving leukocyte 
compartments, rather than the protection of pluripotent 
stem cell compartments. 
The polyclonal mi togens, Con A and LPS, have been 
shown to stimulate relatively mature clones of B & T 
lymphocytes respectively (41). The proliferative response 
of splenic lymphocytes towards these mi togens therefore 
constitutes a measure of mature cell function. 
In the Cy dose titration experiment, T and B 
lymphocyte mi togenesis were found to be dose dependently 
suppressed through 9 days following Cy administration, 
al though T lymphocyte mi togenesis was found to be less 
suppressed on days 3 and 6 than on day 9 (Fig. 6). such 
findings were in excellent agreement with previous reports 
that showed B lymphocytes to be more susceptible to low 
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doses of Cy than T lymphocytes (23, 24, 25, 26). The data 
was also in accord with previous work, which showed T and B 
lymphocyte mitogenesis to be suppressed for at least 10 
days at 200 mg/kg Cy (27). The 150 and 200 mg/kg doses of 
Cy were both shown to induce adequate suppression of T & B 
lymphocyte mitogenesis over the 9 study days. In 
accordance with the guidelines set out in the Rationale, 
the lower of the two doses was selected for use in 
subsequent experiments examining the immunomodulating 
capacities of GR1784 in immunosuppressed mice. This dose 
has also been shown to cause > 50 % inhibition of bone 
marrow cellularity and granulocyte-macrophage CFU (GM-CFU) 
in C57Bl/6 mice by day 4, values returning to normal by day 
10 {21). Furthermore, at this dosage another drug (the 
biologic response modifier MVE-2) was able to restore 
depressed bone marrow cellularity and GM-CFU values (9). 
The administration of Cy at 150 mg/kg in the GR1784 
immunomodulation experiments resulted in a suppression of 
splenic lymphocyte mi togenesis that was more profound in 
the case of B lymphocytes than T lymphocytes (Fig 6). This 
finding confirmed a similar observation made in the Cy dose 
titration experiment and was also in agreement with 
previous reports (23, 24, 25, 26, 27). Although GR1784 was 
not observed to have any effect upon B cell mitogenesis 
(Fig. 6a), it significantly elevated T cell mitogenesis on 
day 2 post Cy administration (Fig 6b). This elevation was 
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not maintained to a significant degree through the next 
assay points on days 9 and 16. It is concluded that this 
partial restoration of a component of the cellular immune 
response might play a part in suppressing the proliferation 
of endogenous pathogens at a critical time following 
irradiation injury. Recovery from irradiation injury has 
been correlated with a gradual return to normal of PBLC's, 
beginning on day 10 following irradiation (13). The 
provision of even a small measure of protection from 
endogenous pathogens during the first 10 days following the 
radiation event may therefore contribute towards enhanced 
irradiation survival. 
On the basis of these results, useful future 
experiments might include an elaboration upon the small 
GRl 784 treatment effect observed on T cell mitogenesis, 
using various doses of Cy and more time points between days 
o and 9. Due to variability in radiation induced death in 
F344 rats, it might also be useful to repeat the radiation 
protection data in the more standard C57Bl/6 mouse model, 
with an additional focus upon the immunological 
responsiveness of the surviving lyrnphocytic compartment. 
SUMMARY 
GRl 784 is an experimental nucleoside drug that has 
been shown to restore suppressed hematological parameters 
in rats following either X-Irradiation or Cyclophosphamide 
(Cy) administration and to provide significant protection 
towards lethal X-Irradiation in rats. 
Experiments were conducted in normal and Cy 
immunosuppressed C57Bl/6 mice, in order to further our 
understanding of the immunological mechanism of action of 
this drug. These demonstrated no immunostimulating effects 
of GRl 784 in normal mice, assessing a number of 
hematological parameters and also mature lymphocyte 
responses towards B and T cell mitogens. GR1784 was found 
to best demonstrate its action within a damaged immune 
system, like another immunomodulator of this family of 
nucleoside drugs, Isoprinosine. 
Previously observed hematorestorative properties 
could not be explained by a direct protective effect on 
pluripotent progenitor cells in the bone marrow or 
relatively mature cell populations in the peripheral blood, 
spleen or bone marrow, following Cy administration. A 
colony forming unit (CFU) assay was employed in order to 
measure the number of colony forming cells (CFC's) in the 
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spleen and bone marrow. This failed to demonstrate any 
potentiating effects of GRl 784 on hematopoiesis following 
hematological insult by Cy. 
A small but significant elevation of depressed T 
lymphocyte mitogenesis in response to Con A was observed on 
day 2 fallowing Cy administration. It is suggested that 
such an increase in responsiveness of the surviving T 
lymphocyte compartment might play a role in warding off the 
surgence of endogenous pathogens that secondarily causes 
death following X-Irradiation and might therefore 
contribute towards GR1784's radioprotective properties. 
l. 
BIBLIOGRAPHY 
Chang T.W., Heel R.C. Ribavirin and Inosiplex : A 
Review of their Present Status in Viral Diseases. 
Drugs 22 : 111-128. (1981) 
2. Binderup L. Effects of Isoprinosine in Animal Models 
of Depressed T Cell Function. Int. J. Immunopharmac. 
]_ 93-101. (1985) 
3. Renoux G., Renoux M., Degenne D. Suppressor Cell 
Activity after Isoprinosine Treatment of Lymphocytes 
from Normal Mice. Int. J. Immunopharmacol. l : 239-
241. (1979) 
4. Renoux G, Renoux M., Guillaumin J.M., Gouzien c. 
Differentiation and Regulation of Lymphocyte 
Populations : Evidence for Immunopotentiation of T 
Cell Recruitment. J. Immunopharmacol. l : 415-422. 
(1979) 
5. Wybran J. Immunomodulatory Properties of Isoprinosine·· 
in Man In Vitro and in Vivo Data. In 
International Symposium on New Trends in Human 
45 
46 
Immunology and cancer Immunotherapy. Serrou B. and 
Rosenfeld c. Eds. Doin Publishers, Paris, pp. 1032-
1037. (1980) 
6. De Simone c., Meli D., Midiri G., Ricca D., Di Paola 
M. Restoration of the Immune Response of Cancer 
Patients with Methisoprinol. XVI International 
Congress of Therapy, Oporto, Minerva Medica. (1981) 
7. Neta R., Douches s., Oppenheim J.J. Interleukin 1 is 
a Radioprotector. J. Immunol. 136 : 2483-2485. 
(1986) 
B. Lohrman H.P., Schreml w. Cytotoxic Drugs and the 
Granulopoietic System. Recent Res. Cancer Res. Bl 
1-22. ( 1982) 
9. Schlick E., Ruffmann R., Chirigos M.A., Welker R.D., 
Herberman R.B. In vitro Modulation of Myelopoiesis 
and Immune Functions by Maleic Anhydride Divinyl 
Ether Copolymer (MVE-2) in Tumour-Free and MBL-2 
Bearing Mice Treated with Cyclophosphamide. ca:ncer 
Res. 45 1108-1114. ( 1985) 
10. Brown C.H., Carbone P.P. Effects of Chemotherapeutic 
agents on Normal Mouse Bone Marrow Grown in vitro. 
47 
Cancer Res. 31 185-190. (1971) 
11. Millard R.E., Blackett N.M., Okell S.F. A Comparison 
of the Effect of Cytotoxic Agents on Agar Colony 
Forming Cells, Spleen Colony Forming Cells, and the 
Erythrocytic Repopulating Ability of Mouse Bone 
Marrow. J. Cell. Physiol. 82 309-318. (1973) 
12. Nikcevich D.A., Young M.R., Ellis N.K., Newby M., 
Wepsic H.T. Stimulation of Hematopoiesis in 
Untreated and Cyclophosphamide Treated Mice by the 
Inhibition of Prostaglandin Synthesis. ~ 
Immunopharmac. ~ 299-313. (1986) 
13. Host H. Comparative Effects of Cyclophosphamide, 
Nitrogen Mustard and Total Body Irradiation on 
Survival and on White Blood Cells in Rats. Radiat. 
Res. ll : 638-651. (1966) 
14. Host H. Regeneration of Bone Marrow Cells in Rats 
Following Cyclophosphamide and Total Body 
Irradiation. Acta. Radiologica. ! 337-352. 
(1966) 
15. De Wys w. D., Goldin A., Mantel N. Hematopoietic 
Recovery after Large Doses of Cyclophosphamide 
48 
Correlation of Proliferative State with Sensitivity. 
Cancer Res. 30 : 1692-1697. (1970) 
16. Nakeff A., McLellan W.L., Bryan J., Valeriote F.A. 
17. 
18. 
Response of Megakaryocyte, Erythrocyte and 
Granulocyte-Macrophage Progenitor Cells in Mouse Bone 
Marrow to Gamma-Irradiation and Cyclophosphamide. In 
. 
. Experimental Haematology Today 1979, pp. 99-104 . 
Baum S. J. , Ledney G.D. Eds. Springer Verlag, New 
York. (1979) 
Valeriote F.A., Collins D.C., Bruce W.R. 
Hematological Recovery in the Mouse Following Single 
Doses of Gamma Radiation and Cyclophosphamide. 
Radiat. Res. 33 501-511. ( 1968) 
Piletic O., Ninkov V., Srnic E. Differences in the 
Reactive Hematopoietic Response of the Spleen and 
Bone Marrow after Treatment with Irradiation and 
Administration of Cytostatic. Hematologica 61 : 45-
60. (1976) 
19. Fried w., Johnson c. The Effect of Cyclophosphamide 
on Hematopoietic Stem Cells. Radiat. Res. 36 : 521-
527. (1968) 
49 
20. Scaro J.L., Barrio-Rendo M.E., de Tombolesi A.R. 
Hematopoietic Recovery after a single Dose of 
Cyclophosphamide in the Mouse. Acta. Physiol. Lat. 
Am. 22 : 258-265. (1972) 
21. Yaeger A.M., Levin F.C., Levin J. Effects of 
Cyclophosphamide on Murine Bone Marrow and Splenic 
Megakaryocyte-CFC, Granulocyte-Macrophage-CFC, and 
Peripheral Blood Cell Levels. J. Cell. Physiol. 112 
: 222-228. (1982) 
22. Marsh J .c. The Effects of Cancer Chemotherapeutic 
Agents on Normal Hematopoietic Precursor Cells A 
Review Cancer Res . .1.§. 1853-1882. ( 1976) 
23. Turk J.L., Poulter L.W. Selective Depletion of 
Lymphoid Tissue by Cyclophosphamide. Clin. Exp. 
Immunol. 10 285-296. (1972) 
24. Turk J.L. Evidence for a Preferential Effect of 
Cyclophosphamide on B Cells. Proc. R. Soc. Med. 66 
805-808. ( 1973) 
25. Stockman G.D., Heim L.R., South M.A., Trentin J.J. 
Differential Effects of Cyclophosphamide on the B & T 
Cell Compartments in Adult Mice. J. Immunol. 110 
50 
277-282. (1973) 
26. Turk J.L., Parker D. The Effect of Cyclophosphamide 
on the Immune Response. J. Immunopharmac. i 127-
137. (1979) 
27. Dumont F. Destruction and Regeneration of Lymphocyte 
Populations in the Mouse Spleen after 
Cyclophosphamide Treatment. Int. Arch. Allergy 47 : 
110-123. (1974) 
28. Nikcevich D.A., Wepsic H.T. Unpublished Data (1985) 
2 9 • Pazdernik T. L. , Uyeki E. M. Cyclophosphamide I. 
Effects on survival and Colony Forming Cells in BDF1 
L-1210-Bearing Mice. J. Pharmacol. Exp. Ther. 207 : 
255-2 61. ( 1978) 
30. Joyce R.A., Hartmann o., Chervenik P.A. Splenic 
Granulopoiesis in Mice Following Administration of 
Cyclophosphamide. Cancer Res. 39 215-218. (1979) 
31. Wierda D., Pazdernik T.L. Effects of Cyclophosphamide 
on Hemic Precursor Cells in Mouse Bone Marrow and 
Spleen. J. Immunopharmac. i 357-376. ( 1979) 
32. 
51 
Smith W., Budd R., Cornfield J. Estimation of 
Radiation Dose Reduction Factor for B-
Mercaptoethylamine by Endogenous Spleen Colony 
Counts. Radiat. Res. 27 363-368. (1966) 
33. Kinnamon K., Ketterling L., Stampfli H., Grenan M. 
34. 
Mouse Endogenous Spleen Counts as a Means of 
Screening for Anti-Irradiation Drugs. Proc. Soc. 
Exp. Biol. Med. 164 370-373. (1980) 
Patchen M.L., MacVittie T.J. Stimulated Hemopoiesis 
and Enhanced survival Following Glucan Treatment in 
Sublethally and Lethally Irradiated Mice. Int. J. 
Immunopharmac. l : 923-932. (1985) 
3 5. Broerse J. J. , Macvi ttie T. J. Response of Different 
36. 
37. 
Species to Whole Body Irradiation. M. Nijhoff, 
Netherlands. (1984) 
Manori I., Kushilevski A., Weinstein Y. 
Interleukin 1 Mediated Radioprotection. 
Immunol. 63 526-532. (1986) 
Analysis of 
Clin. Exp. 
Behling U.H. Beneficial Effects of Endotoxin. A. 
Nowotny Ed., p. 127, Plenum Press, New York. (1983) 
52 
38. Smith F., Smith w., Andrews H., Grenan M. Effect of 
Parenteral Injections of Particulate Matter on 
Survival of X-Irradiated Mice. Am. J. Physiol. 182 : 
396-399. (1955) 
39. Darzynkiewicz z., Traganos F., Sharpless T., Melamed 
M.R. Lymphocyte Stimulation : A Rapid Multiparameter 
Analysis. Proc. Natl. Acad. Sci. USA 73 2881-
2885. (1976) 
40. Sinclair W.K. X-Ray Sensitivity during Cell 
Generation Cycle in Cultured Chinese Hamster Cells. 
Radiat. Res. 29 : 456-461. (1966) 
41. Coutinho A. , Gronowicz E. , Moller G. , Lemke H. 
Mitogens in Immunobiology. J.J. Oppenheim and D.L. 
Rosenstreich Eds., p. 191, Academic Press, New York. 
(1976) 
APPROVAL SHEET 
The thesis submitted by Robert Clive Landis has been read 
and approved by the following committee: 
Dr. Paul Gordon, 
Chairman of committee, 
Adjunct Professor, Microbiology, 
Loyola University of Chicago. 
Dr. Allen Frankfater, 
Associate Professor, Biochemistry, 
Loyola University of Chicago. 
Dr. Charles F. Lange, 
Professor , Microbiology, 
Loyola University of Chicago. 
Dr. Herbert L. Mathews, 
Associate Professor, Microbiology, 
Loyola University of Chicago. 
Dr. Terry Wepsic, 
Associate Professor, Pathology, 
Hines, V.A. Hospital. 
The final copies have been examined by the director of the 
thesis committee and the signature which appears below 
verifies the fact that any neccessary changes have been 
incorporated and that the thesis is now given final 
approval by the committee with reference to content and 
form. 
The thesis is therefore accepted in partial fulfillment of 
the requirements for the degree of Master of Science. 
Date / / 
53 
